This result suggested that TGF-β2 could promote GIST growth by activating the PI3K-AKT signaling pathway, a signal downstream of KIT/PDGFRA, thereby circumventing the direct inhibition of KIT/PDGFRA activity by targeted therapy. Here, TGFB2 is linked to gastrointestinal stromal tumor.